Key Highlights

  • Shares climbed 30.72% over the week, closing at $17.19, though the stock slipped 0.92% on Friday's close from Thursday's post-earnings surge.
  • Second quarter YARTEMLEA net product sales reached $28.5 million, beating consensus estimates of $27.2 million.
  • The company posted Net Income of $13.2 million for the quarter, reversing a $25.4 million net loss in the same period last year.
  • Cash, cash equivalents and short-term investments totaled $132.0 million as of June 30, 2026, following a $240 million upfront payment from the November 2025 sale of zaltenibart to Novo Nordisk.

A Sharp Post-Earnings Rally Gives Back Some Ground

Omeros Corporation (NASDAQ:OMER) shares advanced sharply this week, rising 30.72% to close at $17.19, though the stock pulled back 0.92% on Friday's close after a large portion of the week's gains came in a single post-earnings surge on Wednesday. The Seattle based commercial stage biotechnology company, whose drug YARTEMLEA became the first and only approved inhibitor of the lectin pathway of complement following its December 2025 FDA approval, saw investor enthusiasm build around its early commercial performance before some profit taking set in.

The pattern is common following outsized single day Earnings reactions, where an initial surge on better than expected results is followed by a partial Retracement as investors reassess valuation and lock in gains.

Early Commercial Launch Data Drove the Rally

Second quarter net product sales of YARTEMLEA reached $28.5 million, ahead of the $27.2 million analysts had modeled, with gross-to-net deductions of approximately 11.5%. The company reported that 73 unique accounts had ordered YARTEMLEA by June 30, 2026, representing a 143% increase in ordering accounts since March 31, 2026, as its field force continued engaging the 175 U.S. stem cell transplant centers eligible to prescribe the therapy for transplant associated thrombotic microangiopathy.

The improved commercial trajectory helped drive the company to net income of $13.2 million for the quarter, compared with a net loss of $25.4 million in the same period last year. Results also benefited from an $11.4 million non-cash gain tied to the remeasurement of an embedded derivative on the company's 2029 convertible notes, alongside $6.6 million in net income from discontinued OMIDRIA Royalty operations. Selling, general and administrative expenses rose to $13.9 million from $10.3 million a year earlier, reflecting continued build out of the company's commercial sales organization supporting the YARTEMLEA launch.

Balancing Early Launch Momentum Against Regulatory and Debt Considerations

The durability of this week's rally will likely depend on whether YARTEMLEA's account growth and sales trajectory continue at a similar pace in coming quarters, since a single strong quarter in a recently launched product does not guarantee a sustained ramp. A setback in Europe added a note of caution during the period, as the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion in June 2026 on the company's Marketing authorization application for narsoplimab in the same indication, with a re-examination process now underway.

On the upside, the company's Balance Sheet has been reinforced by proceeds from the November 2025 sale of its zaltenibart program to Novo Nordisk, which included a $240 million upfront payment and eligibility for up to $2.1 billion in additional milestone and royalty payments, providing Capital to fund continued commercialization. Conversely, the company reduced its outstanding 2029 convertible notes through privately negotiated repurchases completed in July 2026, leaving approximately $40.3 million in principal outstanding, a move that trimmed potential dilution but also used cash that could otherwise support commercial expansion.

Conclusion

Omeros' 30.72% weekly advance, tempered by a 0.92% pullback on Friday's close, reflects investor enthusiasm around early YARTEMLEA commercial momentum following a Q2 sales beat and a swing to quarterly profitability. Whether the rally proves durable will likely depend on continued account growth and sales trends in coming quarters, along with the outcome of the pending European regulatory re-examination, neither of which is yet resolved. The reaction illustrates how sharply early stage commercial launch data can move a stock even as questions about sustainability and international approval remain open.